Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2018

View Archived Issues

EDELWEISS phase IIb study of linzagolix achieves primary and secondary endpoints

NINDS grant supports AcuraStem's work in ALS

WindMIL Therapeutics completes series B financing to support development of MILs

DGKZ regulates muscle mass in remodeling and may be a target of therapies against muscle wasting

Kazia Therapeutics presents preliminary phase I data for Cantrixil

Marinus Pharmaceuticals initiates pivotal phase III Marigold Study of ganaxolone

Positive interim phase II data presented for LB-1148 in patients undergoing major surgery

FDA grants regenerative medicine advanced therapy designation to CD34+ cell therapy

RC-48-ADC demonstrates promising antitumor activity in patients with metastatic breast cancer

Boehringer Ingelheim identifies free fatty acid receptor 1 agonists

Allena Pharmaceuticals completes preclinical proof-of-concept study for ALLN-346

Genentech, Roche and Paraza Pharma patent TRPA1 antagonists

Andes-1537 well tolerated in phase I study, dose expansions planned

Monalizumab shows promising activity in combination with durvalumab in MSS-CRC

Seattle Children's initiates phase I trial of CAR T-cell therapy for pediatric CNS tumors

Can-Fite updates status of phase II trial of namodenoson in advanced HCC

Kala updates registration plan for KPI-121 for short-term treatment of dry eye disease

Idorsia initiates phase III study of aprocitentan for resistant hypertension

Tumor mutations can aid variant calling for germline

Clinical benefit noted with NIR-178 in patients with non-small cell lung cancer

Argenx reports cohort 1 interim data from phase II study of efgartigimod in pemphigus vulgaris

IDMC recommends continuation of phase III study of masitinib for metastatic CRPC

Sarepta reports preliminary data from phase I/IIa gene therapy trial in Duchenne muscular dystrophy

ACY-1215 in combination with nab-paclitaxel shows promising activity in metastatic breast cancer

CStone initiates phase I trial in Australia with MEK inhibitor CS-3006